Back to Results
First PageMeta Content
Organic chemistry / Peptide hormones / Diabetes / Dipeptidyl peptidase-4 inhibitors / Eli Lilly and Company / Anti-diabetic medication / Exenatide / Lixisenatide / Sitagliptin / Anti-diabetic drugs / Chemistry / Endocrine system


Document Date: 2010-09-03 10:29:03

Open Document

File Size: 580,13 KB

Share Result on Facebook

Company

Mitsubishi / Eli Lilly / Johnson & Johnson / LG / Novartis / Japan Tobacco / Metabolex / Boehringer Ingelheim / Incyte / Roche / GlaxoSmithKline / Merck / Biodel / TransTech Pharma / AstraZeneca / Novo Nordisk / Bristol-Myers Squibb / Elite Pharmaceuticals Inc. / /

Continent

North America / Europe / /

Country

Japan / United States / /

Currency

USD / /

Event

FDA Phase / Earnings Announcement / /

Facility

Novo Nordisk’s pipeline / Diabetes Pipeline / /

IndustryTerm

biological products / Treatment of diabetes / non-recombinant products / established products / insulin products / combination products / modified insulin products / /

MedicalCondition

Summary Diabetes mellitus / obesity / hypersensitivity / II diabetes / highly prevalent disease / I diabetes / disease / hyperglycemia / diabetes / acute coronary syndrome / diabetes mellitus / autoimmune disease / /

Organization

FDA / /

Position

Executive / /

Product

NovoLog / pioglitazone / Janumet / TGR5 / Byetta / Avandamet / Actoplus Met / Humalog / glimepiride / Lantus / Levemir / Prandin / repaglinide / Actos / Canagliflozin / Amaryl / Januvia / Avandia / rosiglitazone / GSK-184072 / MBX-2982 / TT-223 / VIAject / three / INCB-13739 / Europe / Japan / JTT-654 / Three oral / BI-10773 / GLP-1 / HSD1 / Phase II / GSK-1362885 / /

URL

www.InsightPharmaReports.com / /

SocialTag